GoodRx (NASDAQ:GDRX) Price Target Lowered to $6.25 at Citigroup

GoodRx (NASDAQ:GDRX - Get Free Report) had its target price cut by analysts at Citigroup from $7.00 to $6.25 in a report issued on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. Citigroup's target price would suggest a potential upside of 37.36% from the company's previous close.

Several other analysts have also recently commented on GDRX. KeyCorp reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday. Barclays reduced their price objective on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a research report on Monday, November 11th. Mizuho assumed coverage on GoodRx in a research report on Wednesday, December 4th. They set a "neutral" rating and a $5.00 target price on the stock. Finally, Morgan Stanley reduced their price target on GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Five analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $8.38.

GoodRx Stock Performance

Shares of NASDAQ GDRX traded up $0.27 during mid-day trading on Friday, hitting $4.55. 1,945,975 shares of the company were exchanged, compared to its average volume of 1,349,529. The stock has a 50 day simple moving average of $4.72 and a 200-day simple moving average of $6.57. GoodRx has a 1-year low of $4.09 and a 1-year high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -151.67, a price-to-earnings-growth ratio of 3.43 and a beta of 1.27.

Hedge Funds Weigh In On GoodRx

Several hedge funds have recently added to or reduced their stakes in GDRX. Fortem Financial Group LLC acquired a new position in shares of GoodRx in the third quarter worth $772,000. Charles Schwab Investment Management Inc. raised its stake in GoodRx by 5.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company's stock valued at $3,332,000 after purchasing an additional 26,262 shares during the last quarter. Barclays PLC raised its stake in GoodRx by 1,316.1% in the 3rd quarter. Barclays PLC now owns 140,113 shares of the company's stock valued at $973,000 after purchasing an additional 130,219 shares during the last quarter. Raymond James & Associates lifted its holdings in GoodRx by 212.6% in the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company's stock valued at $2,734,000 after purchasing an additional 267,951 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd boosted its stake in shares of GoodRx by 260.7% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company's stock worth $308,000 after purchasing an additional 32,104 shares during the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.